Newron Pharmaceuticals SpA
http://www.newron.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Newron Pharmaceuticals SpA
Newron Enters New Year With High Hopes For Evenamide
All being well, the Italian firm will soon have the results from a late-stage study of evenamide in schizophrenia patients who show an inadequate response to atypical antipsychotics.
Companies Advised To ‘Re-Think’ SPC & Regulatory Strategies For ‘Loose’ Combination Products
A key problem with obtaining supplementary protection certificates for combination drug therapies, particularly for “add-on” therapies where patients have access to the remaining active components, was highlighted in a UK court case judgement, the principle of which is expected to be followed in Europe.
First Clinical Safety Study Starts For Newron's Evenamide
Following safety issues raised by the US FDA, no toxicity concerns have emerged in preclinical studies of Newron’s candidate schizophrenia therapy, evenamide, and a clinical safety study has started to evaluate its CNS effects.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice